Literature DB >> 17345074

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM.

Grant Langdon1, Ivelina Gueorguieva, Leon Aarons, Mats Karlsson.   

Abstract

PURPOSE: The aim of this study was to evaluate the performance of the NONMEM prior functionality compared to a full Bayesian method when applied to population physiological models using diazepam as a case study.
METHODS: Whole-body physiologically based pharmacokinetic (WBPBPK) models for diazepam were initially developed, tested and calibrated for rats and man using a full Bayesian analysis as implemented in WINBUGS: . The final models were implemented in NONMEM and the results from the two analyses compared in terms of parameter estimates, measures of parameter precision and run times.
RESULTS: NONMEM population parameter estimates were in close agreement with those produced by the Bayesian analysis although there was a substantial shortening of run time for both the animal WBPBPK model (4.5 vs. 21 h) and human WBPBPK models (2 vs. 167 h). The adequacy of the model and the final parameter estimates were judged to be sufficient by the model's ability to describe individual tissue concentration-time profiles. The model provided a good overall description of the plasma concentration-time data in both rat and man with comparable parameter precision. A limited nonparametric bootstrap (n = 50) was performed to assess parameter sensitivity, bias and imprecision. No systematic bias was seen when comparing bootstrap means to final parameter estimates.
CONCLUSIONS: The ease of implementation and reductions in run time hopefully provide a further step forward in allowing the wider use of these complex and information-rich models together with clinical data in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17345074     DOI: 10.1007/s00228-007-0264-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

Authors:  Patrick Poulin; Frank-Peter Theil
Journal:  J Pharm Sci       Date:  2002-01       Impact factor: 3.534

Review 2.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios.

Authors:  Ivelina Gueorguieva; Ivan A Nestorov; Susan Murby; Sophie Gisbert; Brent Collins; Kelly Dickens; Judith Duffy; Ziad Hussain; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

4.  Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed.

Authors:  L Aarons
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

5.  Analysis of population pharmacokinetic data using NONMEM and WinBUGS.

Authors:  Stephen B Duffull; Carl M J Kirkpatrick; Bruce Green; Nicholas H G Holford
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

6.  Comparison of Bayesian and maximum-likelihood inference of population genetic parameters.

Authors:  Peter Beerli
Journal:  Bioinformatics       Date:  2005-11-29       Impact factor: 6.937

7.  Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

Authors:  Ivelina Gueorguieva; Leon Aarons; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-29       Impact factor: 2.745

8.  Use of prior information to stabilize a population data analysis.

Authors:  Per O Gisleskog; Mats O Karlsson; Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

9.  Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model.

Authors:  Y Igari; Y Sugiyama; Y Sawada; T Iga; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

10.  Regional blood flow in conscious resting rats determined by microsphere distribution.

Authors:  I Kuwahira; N C Gonzalez; N Heisler; J Piiper
Journal:  J Appl Physiol (1985)       Date:  1993-01
View more
  17 in total

1.  Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.

Authors:  Massimo Cella; Catherijne Knibbe; Saskia N de Wildt; Joop Van Gerven; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 2.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

3.  Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim.

Authors:  Periklis Tsiros; Frederic Y Bois; Aristides Dokoumetzidis; Georgia Tsiliki; Haralambos Sarimveis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-04       Impact factor: 2.745

4.  Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus dose.

Authors:  S Y A Cheung; T Rodgers; L Aarons; I Gueorguieva; G L Dickinson; S Murby; C Brown; B Collins; M Rowland
Journal:  Br J Pharmacol       Date:  2017-12-01       Impact factor: 8.739

5.  Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?

Authors:  Massimo Cella; Wei Zhao; Evelyne Jacqz-Aigrain; David Burger; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

6.  Well-tempered MCMC simulations for population pharmacokinetic models.

Authors:  Frederic Y Bois; Nan-Hung Hsieh; Wang Gao; Weihsueh A Chiu; Brad Reisfeld
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-07-31       Impact factor: 2.745

7.  A physiologically-based recirculatory meta-model for nasal fentanyl in man.

Authors:  Richard N Upton; David J R Foster; Lona L Christrup; Ola Dale; Kristin Moksnes; Lars Popper
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-19       Impact factor: 2.745

8.  Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

Authors:  Nikolaos Tsamandouras; Thierry Wendling; Amin Rostami-Hodjegan; Aleksandra Galetin; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-05-26       Impact factor: 2.745

9.  Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin.

Authors:  Andrés Olivares-Morales; Avijit Ghosh; Leon Aarons; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-09-08       Impact factor: 4.009

10.  Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.

Authors:  Nikolaos Tsamandouras; Gemma Dickinson; Yingying Guo; Stephen Hall; Amin Rostami-Hodjegan; Aleksandra Galetin; Leon Aarons
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.